Summary
69 / 100 · Bulios Score
What speaks for it
- Revenue grew by 13% a year over the last 3 years.
- It bought back its own shares for $75.6M in the last fiscal year, 6.5% of its market value.
- Out of every 100 USD of revenue, 11 USD is left as net profit.
What to watch
- The share price is above the Bulios Fair Price.
- It missed profit estimates 4 times in the last 8 quarters.
- It earns only 5.9 USD a year on every 100 USD of invested capital.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 14.8 USD for 1 USD of yearly profit. Over the last five years it was 16.8 USD on average.
Valuation in detailIs it growing?
Yes, fastRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 16% a year over 5 years. Over the last 3 years it grew by 13% a year. Earnings per share grew by 5.3% a year over the last 3 years.
Growth in detailDoes it make money?
Very wellWhere 100 USD of revenue goes
- Cost of sales 52 USD
- Research and development 13 USD
- Sales and administration 19 USD
- Taxes and other 4.9 USD
- Net profit 11 USD
Net profit, industry median (Drug Manufacturers - Specialty & Generic) 10 USD
Out of every 100 USD of revenue, 11 USD is left as net profit.
Profitability in detailIs it financially healthy?
MostlyRepaying all its debt would take 4.5 years of free cash flow. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Neutral- Buy 3
- Hold 8
- Sell 1
Today's price within the analysts' price targets
The average target of $21.25 is 18% below today's price. 25% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- Epinephrine 100%
By region
- UNITED STATES 95%
- France 4.9%
- China 0.4%
Epinephrine brings in 100% of revenue.
Segments in detail